Indication
Imreplys is indicated for treatment of patients of all ages acutely exposed to myelosuppressive doses of radiation with Haematopoietic Sub-syndrome of Acute Radiation Syndrome (H-ARS). Imreplys should be used in accordance with official radiological/nuclear emergency recommendations.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
Documents
The official texts, at the regulator.